English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 21 September 2022, 19:00 HKT/SGT
Share:
    

Source: Malaysian Genomics Resource Centre Bhd
Malaysian Genomics, Rinani Genotec Sign LOI with Universiti Malaysia Sabah
Parties agree to collaborate on research in genetics, regenerative and alternative medicine

PETALING JAYA, Malaysia, Sept 21, 2022 - (ACN Newswire) - Leading genomics and biopharmaceutical specialist Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155) is pleased to report that the Group has signed a letter of intent (LOI) with the Faculty of Science and Natural Resources, Universiti Malaysia Sabah (UMS) and Rinani Genotec Sdn Bhd (Genotec) to collaborate on research and development (R&D) in genetics, and regenerative and alternative medicines.

Chairman of Malaysian Genomics, Datuk Seri Dr. Chen Chaw Min

Under the LOI, MGRC, which owns a high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, as well as Genotec, which specializes in biomedical treatments using stem cells, will assist in strengthening the teaching and research activities of the undergraduate programme at UMS' Faculty of Science and Natural Resources.

This cooperation will enable the exchange of research resources and ideas to enhance the quality of research at UMS, as well as create opportunities for students from the Faculty of Science and Natural Resources to serve their internship period at MGRC or Genotec.

Chairman of Malaysian Genomics, Datuk Seri Dr. Chen Chaw Min, said, "We are happy to assist UMS undergraduates in pursuing their R&D goals so that they have a better understanding of their field of study. This is also in support of the National Biotechnology Policy 2.0 launched recently focusing on agriculture and food security, healthcare and wellbeing, as well as industrial and the circular economy."

The Dean of the Faculty of Science and Natural Resources, UMS, Professor Dr. Jualang Azlan Gansau said, "UMS is actively engaging in research as well as teaching activities and the involvement of industry is crucial in ensuring the relevance of such activities conducted at the University."

The signing of the LOI followed UMS' visit to MGRC's Biosafety Level 2 cGMP (Current Good Manufacturing Practice)-certified laboratory, which is used for the production of cell therapies, including CAR T-cell therapies for various cancers.

Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/

Topic: Press release summary
Source: Malaysian Genomics Resource Centre Bhd

Sectors: Daily News, BioTech, Healthcare & Pharm, Local Biz
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Malaysian Genomics Resource Centre Bhd Related News
Aug 29, 2023 13:00 HKT/SGT
Malaysian Genomics Unveils Strategic Advances in Biopharmaceuticals
May 15, 2023 18:00 HKT/SGT
Malaysian Genomics Inks Agreement in Expansion to Bangladesh
Feb 27, 2023 13:00 HKT/SGT
Malaysian Genomics to Boost Play on the Football Pitch
Feb 24, 2023 17:30 HKT/SGT
Malaysian Genomics Pivots to Biopharmaceuticals for Growth
Feb 24, 2023 13:30 HKT/SGT
Malaysian Genomics to Collaborate on Cannabinoid R&D
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575